```json
{
"content": [
{
"type": "faq",
"items": [
{
"Q": "What is the current market size?",
"A": "The progesterone prog market size was valued at approximately USD 1.2 billion in 2023, driven by increasing demand for women’s health and hormonal therapies, as per a 2023 industry report."
},
{
"Q": "What is the expected growth rate?",
"A": "The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, reaching USD 1.8 billion, fueled by rising hormonal disorder diagnoses and advancements in drug delivery systems."
},
{
"Q": "What are the primary growth drivers?",
"A": "Key drivers include rising infertility treatment adoption, growing menopause therapy demand, and increased healthcare spending in emerging economies due to aging populations."
},
{
"Q": "What challenges does the market face?",
"A": "Regulatory hurdles, generic drug competition, and side effect concerns are major challenges, particularly due to patent expirations and stringent safety evaluations."
},
{
"Q": "Which regions are leading the market?",
"A": "North America leads the market with advanced healthcare infrastructure, while Asia-Pacific is emerging rapidly due to patient awareness growth and expanding pharma companies."
},
{
"Q": "Who are the leading companies?",
"A": "Key players include Merck & Co., Ferring Pharmaceuticals, and AbbVie Inc., focusing on innovation and partnerships to strengthen their market position."
},
{
"Q": "What are the key future opportunities?",
"A": "Opportunities lie in biosimilar development, expansion into underserved regions, and integrating digital health tools for personalized hormone therapy, reflecting a positive future outlook."
},
{
"Q": "How does technology impact the market?",
"A": "Advancements in biologics, nanotechnology, and AI-driven diagnostics improve drug delivery and patient outcomes, enhancing the progesterone prog market’s efficiency and adoption."
},
{
"Q": "What is the regulatory landscape?",
